Novel Foods and Genetically Modified Foods: Safety Assessment

Novel foods are foods without a significant history of consumption in a given market - including foods from new sources, new production processes, or genetic modification - and their safety assessment is the pre-market scientific evaluation that decides whether they may be sold. For genetically modified foods this assessment is built around comparison with an established conventional counterpart.

Definition

Safety assessment of novel and genetically modified foods is the structured pre-market evaluation of a food lacking a history of safe use, in which its composition, potential toxicity, allergenicity, and nutritional impact are characterised - for genetically modified foods, by comparison with a conventional counterpart presumed safe.

Scope

The topic covers what counts as a novel food, the principle of substantial equivalence and comparative safety assessment, the data typically required (compositional, toxicological, allergenicity, and nutritional), and the regulatory frameworks that authorise such foods. It is a reference and educational entry on how these foods are assessed for safety, not advice on their consumption or on regulatory submissions for a specific product.

Core questions

• What makes a food "novel" and therefore subject to pre-market assessment?
• How does the comparative (substantial-equivalence) approach structure the safety assessment of genetically modified foods?
• What compositional, toxicological, allergenicity, and nutritional data are evaluated?
• How do regulatory frameworks decide whether a novel food may be authorised?

Key concepts

• Novel food
• Substantial equivalence
• Comparative safety assessment
• Conventional counterpart
• Compositional analysis
• Allergenicity assessment
• Pre-market authorisation

Key theories

Substantial equivalence

The principle that a genetically modified food shown to be compositionally and nutritionally equivalent to an established conventional counterpart can be treated as comparably safe, so that assessment focuses on identified differences rather than re-evaluating the whole food; it serves as a starting point for, not a substitute for, the safety assessment.

Mechanisms

The assessment begins by identifying an appropriate conventional comparator with a history of safe use. The novel food is then characterised against that comparator - its composition, any introduced genes or proteins, potential toxicity, allergenicity, and nutritional consequences are examined. Where the food is found substantially equivalent except in defined respects, the evaluation concentrates on those differences; where it is not, a more comprehensive assessment is required. The output is a judgement on whether the food is as safe as its counterpart under the intended conditions of use.

Clinical relevance

The safety assessment of novel and genetically modified foods determines what new foods reach the market and underpins public confidence in their safety, which is relevant context for dietary counselling and public health. The topic describes how such foods are evaluated and is not a basis for individual dietary or medical decisions.

Evidence & guidelines

Internationally, the Codex Alimentarius provides principles and guidelines for the safety assessment of foods derived from modern biotechnology, while regional authorities such as EFSA issue detailed guidance for novel food and genetically modified food applications. These guidance documents constitute the principal evidence base; the substantial-equivalence concept is discussed in the methodological literature.

History

The comparative, substantial-equivalence approach was articulated by international bodies in the early 1990s and elaborated through Codex and regional regulation as genetically modified crops entered the food supply. Dedicated novel-food regulation - covering not only genetic modification but also new sources and processes - developed in parallel, with frameworks periodically revised as new technologies emerged.

Debates

Is substantial equivalence a sufficient basis for safety assessment?

Critics have argued that equivalence is a vague starting concept rather than a safety test in itself, while proponents hold that, used as a structured comparison to focus assessment on identified differences, it is an appropriate and practical paradigm for evaluating genetically modified foods.

Seminal works

• kuiper-2002
• efsa-2024-novelfood

Frequently asked questions

What is substantial equivalence?

It is the principle that if a genetically modified food is shown to be compositionally and nutritionally equivalent to an established conventional food, it can be regarded as comparably safe, so the safety assessment focuses on any identified differences rather than re-evaluating the entire food from scratch.

Are novel foods assessed before they can be sold?

Yes. In jurisdictions with novel-food frameworks, foods lacking a significant history of safe consumption require a pre-market safety assessment - covering composition, toxicity, allergenicity, and nutrition - and an authorisation decision before they may be placed on the market.